Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for military-related posttraumatic stress disorder.  For more information, please visit www.thehonorstudy.com or www.clinicaltrials.gov (NCT03062540).

Research & Development
: Scientific Presentations

Scientific Presentations

Bedtime, Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia: Results of a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study

Poster Presentation at the American College of Rheumatology (ACR) 2015 Annual Meeting in San Francisco, CA

Lederman S, Gendreau RM, Clauw DJ, Arnold LM, Gendreau J, Daugherty B, Forst A. Bedtime, Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia: Results of a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study [abstract]. Arthritis Rheumatol. 2015; 67 (Suppl 10).

Uploaded: Nov 10, 2015
Type: Pdf

Relationship of Sleep Quality and Fibromyalgia Outcomes in a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of Bedtime, Rapidly Absorbed, Sublingual Cyclobenzaprine (TNX-102 SL)

Poster Presentation at the American College of Rheumatology (ACR) 2015 Annual Meeting in San Francisco, CA

Moldofsky H, Gendreau RM, Clauw DJ, Gendreau J, Vaughn B, Daugherty B, Forst A, Sullivan G, Lederman S. Relationship of Sleep Quality and Fibromyalgia Outcomes in a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of Bedtime, Rapidly Absorbed, Sublingual Cyclobenzaprine (TNX-102 SL) [abstract]. Arthritis Rheumatol. 2015; 67 (Suppl 10).

Uploaded: Nov 10, 2015
Type: Pdf

Responder Compared to Mean Change Analyses in a Fibromyalgia Phase 2b Clinical Study of Bedtime Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL)

Poster Presentation at the American College of Rheumatology (ACR) 2015 Annual Meeting in San Francisco, CA

Gendreau RM, Clauw DJ, Gendreau J, Daugherty B, Lederman S. Responder Compared to Mean Change Analyses in a Fibromyalgia Phase 2b Clinical Study of Bedtime Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) [abstract]. Arthritis Rheumatol. 2015; 67 (Suppl 10).

Uploaded: Nov 10, 2015
Type: Pdf

The AtEase Study: An Evaluation of the Efficacy of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD

Poster Presentation at the Military Health System Research Symposium (MHSRS) 2015 Annual Meeting in Fort Lauderdale, FL

Sullivan GM, Gendreau JF, Gendreau RM, Schaberg A, Daugherty BL, Jividen H, Peters A, Peters P, Lederman S. The AtEase Study: An Evaluation of the Efficacy of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD. Poster session presented at: 2015 Military Health System Research Symposium (MHSRS); 2015 Aug 17-21; Ft. Lauderdale, FL.

Uploaded: Aug 18, 2015
Type: Pdf

(R)-isometheptene* (IMH) Binds to the Imidazoline-1 Receptor and (S)-IMH increases Blood Pressure: Potentially Superior Benefit-to-Risk Ratio for (R)-IMH as an Analgesic for Headache

Poster Presentation at the American Headache Society (AHS) 2015 Annual Meeting in Washington, DC

Daugherty B, Gershell L, Lederman S. (R)-Isometheptene (IMH)* Binds to the Imidazole-1 Receptor and (S)-IMH Increases Blood Pressure: Potentially Superior Benefit to Risk Ratio for (R)-IMH as an Analgesic for Headache. Headache. 2015; 55: 172.

Uploaded: Jun 22, 2015
Type: Pdf

The (R)- isomer of isometheptene*, decreases trigeminal sensitivity in the Inflammatory Soup and Spontaneous Trigeminal Allodynia rat models

Poster Presentation at the American Headache Society (AHS) 2015 Annual Meeting in Washington, DC

Fried NT, Oshinsky ML, Daugherty BL, Lederman S, Elliott MB. The (R)-isomer of Isometheptene*, decreases Trigeminal Sensitivity in a Rat Model of Primary Headache. 2015; 55: 184.

Uploaded: Jun 22, 2015
Type: Pdf

TNX-102 SL* for the Treatment of Fibromyalgia: Role of Nonrestorative Sleep on Pain Centralization

Poster Presentation at the European Union League Against Rheumatism (EULAR) 2015 Annual Meeting in Rome, IT

Lederman S, Clauw D, Gendreau JF, Arnold L, Moldofsky H, Mease P, Daugherty BL, Gendreau RM. THU0325 TNX-102 SL for the Treatment of Fibromyalgia: Role of Nonrestorative Sleep on Pain Centralization. Ann Rheum Dis. 2015; 74(Suppl 2): 313.

Uploaded: Jun 11, 2015
Type: Pdf

TNX-102 SL* for Treatment of Fibromyalgia: Approaches to Pain Measurement

Poster Presentation at the European Union League Against Rheumatism (EULAR) 2015 Annual Meeting in Rome, IT

Gendreau RM, Clauw D, Gendreau JF, Daugherty BL, Lederman S. THU0322 TNX-102 SL for Treatment of Fibromyalgia: Approaches to Pain Measurement. Ann Rheum Dis. 2015; 74(Suppl 2): 312.

Uploaded: Jun 11, 2015
Type: Pdf

Serotonin Receptor Profiles of Bedtime Pharmacotherapies Targeting Posttraumatic Stress Disorder (PTSD)

Poster Presentation at the Society of Biological Psychiatry 2015 Annual Meeting in Toronto, CA

Daugherty B, Sullivan G, Gershell L, Lederman S. 728. Serotonin Receptor Profiles of Bedtime Pharmacotherapies Targeting Posttraumatic Stress Disorder (PTSD). Biological Psychiatry. 2015; 77(Suppl 1): 271S-272S.

Uploaded: May 19, 2015
Type: Pdf

Cyclobenzaprine (CBP) and its Major Metabolite Norcyclobenzaprine (nCBP) are Potent Antagonists of the Serotonin Receptor 2A, Histamine H1 and α-Adrenergic Receptors: Mechanistic and Safety Implications...

Poster Presention in November 2013 at the American College of Rheumatology Annual Meeting.

Bruce Daugherty, PhD; Leland Gershell, MD, PhD; Seth Lederman, MD

Uploaded: Nov 13, 2012
Type: Pdf
<< Previous 1 | 2 | 3